AI-Powered Algorithm Gets FDA 501(k) Clearance for Detection of Subarachnoid Hemorrhages
A recent study found that Viz ANEURYSM had a 94 percent accuracy rate of diagnosing subarachnoid hemorrhages on computed tomography angiography (CTA).
Excerpt from the Press Release:
Subarachnoid hemorrhages reportedly affect nearly 30,000 Americans each year and have a 40 percent mortality rate. However, Viz ANEURYSM, a new artificial intelligence (AI)-powered algorithm, may improve the diagnosis of subarachnoid hemorrhages and facilitate more timely intervention and follow-up, according to the manufacturer Viz.ai.
Viz ANEURYSM, which recently garnered 510(k) clearance from the Food and Drug Administration (FDA), was the subject of a 2020 study presented at the International Stroke Conference by researchers from the University of Toronto. Researchers assessed the use of the algorithm on 528 computed tomography angiography (CTA) scans that revealed a total of 674 aneurysms. Viz.ai said the study revealed a 94 percent accuracy rate for Viz ANEURYSM.
“(Aneurysms) can often be missed because they require a very methodical diagnostic approach,” noted lead study author Vitor Mendes Pereira, MSc, MD, the director of endovascular research and innovation at the University of Toronto. “The model has demonstrated that a deep learning AI algorithm can achieve clinically useful levels of accuracy for clinical decision support and will help us to improve how we help aneurysm patients.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?